Literature DB >> 15265485

C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors.

Nobuyuki Matsunaga1, Tomohiro Kaku, Akio Ojida, Toshimasa Tanaka, Takahito Hara, Masuo Yamaoka, Masami Kusaka, Akihiro Tasaka.   

Abstract

A series of 1- and 4-(2-naphthylmethyl)-1H-imidazoles (3 and 4) has been synthesized and evaluated as C(17,20)-lyase inhibitors. Several 6-methoxynaphthyl derivatives showed potent C(17,20)-lyase inhibition, suppression of testosterone biosynthesis in rats and reduction in the weight of prostate and seminal vesicles in rats, whereas most of these compounds increased the liver weight after consecutive administrations. The effect on the liver weight was removed by incorporation of a hydroxy group and an isopropyl group at the methylene bridge, as seen in (S)-28d and (S)-42. Selectivity for C(17,20)-lyase over 11beta-hydroxylase is also discussed, and (S)-42 was found to be a more than 260-fold selective inhibitor. Furthermore, (S)-42 showed a potent suppression of testosterone biosynthesis after a single oral administration in monkeys. These data suggest that (S)-42 may be a promising agent for the treatment of androgen-dependent prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265485     DOI: 10.1016/j.bmc.2004.06.016

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

Review 1.  Novel options for the treatment of castration-resistant prostate cancer.

Authors:  Carsten-H Ohlmann; Axel S Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J Mathers; Patrick J Bastian
Journal:  World J Urol       Date:  2011-11-20       Impact factor: 4.226

Review 2.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

Review 3.  Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

Review 4.  Beyond castration-defining future directions in the hormonal treatment of prostate cancer.

Authors:  Saroj Niraula; Kim Chi; Anthony Michael Joshua
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

5.  An Easy Access to Furan-Fused Polyheterocyclic Systems.

Authors:  Alice Benzi; Lara Bianchi; Gianluca Giorgi; Massimo Maccagno; Giovanni Petrillo; Domenico Spinelli; Cinzia Tavani
Journal:  Molecules       Date:  2022-05-14       Impact factor: 4.927

6.  Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.

Authors:  R Leibowitz-Amit; A M Joshua
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

7.  Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus.

Authors:  Bogdan Tarus; Hélène Bertrand; Gloria Zedda; Carmelo Di Primo; Stéphane Quideau; Anny Slama-Schwok
Journal:  J Biomol Struct Dyn       Date:  2014-11-19

8.  Direct observation of redox reactions in Candida parapsilosis ATCC 7330 by Confocal microscopic studies.

Authors:  Sowmyalakshmi Venkataraman; Shoba Narayan; Anju Chadha
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 9.  Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer.

Authors:  Saber H Saber; Hamdy E A Ali; Rofaida Gaballa; Mohamed Gaballah; Hamed I Ali; Mourad Zerfaoui; Zakaria Y Abd Elmageed
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

Review 10.  Dihydronaphthofurans: synthetic strategies and applications.

Authors:  Abolfazl Olyaei; Mahdieh Sadeghpour
Journal:  RSC Adv       Date:  2020-02-05       Impact factor: 4.036

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.